RF GP Ablation Added to PEF PVI for Paroxysmal AF (REGATTA-AF)
RadiofrEquency Ablation of Ganglionated Plexi Added to The Pulsed ElecTric Field Pulmonary Vein Isolation for PAroxysmal Atrial Fibrillation (REGATTA-AF Study)
This study will investigate whether adjunctive RF GP ablation, when added to PF PVI, improves freedom from AF or atrial tachycardia (AT). By directly addressing the potential limitation of autonomic modulation associated with PF ablation alone, this study will provide mechanistic and clinically relevant insights into the role of parasympathetic modulation of the heart in preventing AF recurrence.
The results are expected to yield novel, clinically meaningful evidence that may help refine and optimize catheter ablation workflows, particularly in the era of non-thermal energy sources.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and pulmonary vein isolation (PVI) represents the cornerstone therapeutic strategy in patients with symptomatic paroxysmal AF. Pulsed electric field (PEF) ablation is a novel energy source that enables safe and durable PVI but has a limited and only transient effect on the autonomic nervous system, which plays an important role in the pathogenesis of AF. Previous studies have shown that modification of ganglionated plexi (GP) using radiofrequency (RF) energy may result in more effective and sustained parasympathetic atrial denervation, thereby potentially improving long-term ablation outcomes.
The aim of this project is to compare the efficacy of PEF PVI alone versus a combined strategy of PEF PVI plus adjunctive RF GP ablation in patients with antiarrhythmic drug-refractory paroxysmal AF. This is a multicentre, randomized, single-blind superiority trial. A total of 250 patients will be enrolled across three highly specialized centres in the Czech Republic. The primary endpoint is freedom from recurrent AF/atrial tachycardia lasting >30 seconds during 12 months of follow-up (excluding a 2-month blanking period) without the use of Class I/III antiarrhythmic drugs. Secondary endpoints include arrhythmia burden assessed by long-term ECG monitoring, quality of life, procedural safety, and detailed evaluation of cardiac autonomic function using both invasive and non-invasive methods.
The project will provide the first direct clinical evidence on the benefit of targeted autonomic modulation added to PEF PVI. The results may substantially influence the optimization of ablation strategies in paroxysmal AF and contribute to the refinement of future clinical guidelines.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Prague
-
Prague, Prague, Tschechien, 14200
- Institute for Clinical and Experimental Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patients with drug-resistant symptomatic paroxysmal AF meeting all the following criteria:
- Paroxysmal AF that terminates spontaneously or with intervention within 7 days of onset.
- Failed AAD treatment, defined as ineffective, intolerant or inappropriate ≥1 Class I-IV AAD.
-
Patients who are ≥30 and ≤65 years of age on the day of enrolment.
-
Patients who are willing and capable of:
- Providing informed consent to undergo study procedures AND
- Participating in all examinations, follow-up visits, and tests associated with this clinical study.
-
Effective contraception for women of childbearing potential.
-
Effective oral anticoagulation for >3 weeks before the planned ablation procedure.
Exclusion Criteria:
- Persistent, long-standing persistent, or permanent AF.
- AF secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
- Left atrial (LA) anteroposterior diameter ≥50 mm (by transthoracic echocardiography).
- Left ventricular ejection fraction <40%.
- Autonomic dysfunction, e.g., cardiac autonomic neuropathy due to diabetes mellitus.
- Any prior atrial endocardial or epicardial ablation procedure, including cavotricuspid isthmus (CTI) ablation or right-sided AT.
- Any prior atrial surgery.
- Intra-atrial septal patch or interatrial shunt.
- General contraindications of catheter ablation
- LA appendage closure, device, or occlusion, past or anticipated.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: RF GP + PEF PVI
Radiofrequency ablation of ganglionated plexi added to pulmonary vein isolation and roof line ablation using pulsed electric field |
isolation of pulmonary veins and roof line ablation using pulsed electric energy ablation of GP using radiofrequency energy |
|
Aktiver Komparator: PEF PVI
Pulmonary vein isolation and roof line ablation using pulsed electric field energy |
isolation of pulmonary veins and roof line ablation using pulsed electric energy |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Freedom from recurrent AF/AT >30 s during the first 12 months
Zeitfenster: From the ablation procedure through the 12-month follow-up.
|
The primary outcome of the study is freedom from recurrent AF/AT >30 s during the first 12 months (excluding a 2-month blanking period) after the procedure without the use of Class I or III AADs. |
From the ablation procedure through the 12-month follow-up.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Quality of life
Zeitfenster: Baseline and at the 12-month visit.
|
This measure will be assessed by the AFEQT questionnaire. A higher score = a better quality of life (0 = worst possible quality of life, 50 = intermediate impairment, and 100 = best possible quality of life). |
Baseline and at the 12-month visit.
|
|
Periprocedural complications, MACE
Zeitfenster: From the ablation procedure through the 12-month follow-up.
|
periprocedural complications, including cardiac tamponade, stroke/TIA, major bleeding requiring intervention or transfusion, vascular access complications requiring treatment; major adverse cardiac events during follow-up |
From the ablation procedure through the 12-month follow-up.
|
|
Acute vagal denervation assessed by ECVS
Zeitfenster: Periprocedural
|
ECVS will be performed during the ablation procedure at baseline and 20 minutes after the last PF of RF application. The longest P-P and R-R pauses ( in seconds) during ECVS will be recorded. |
Periprocedural
|
|
Long-term cardiac vagal denervation
Zeitfenster: Baseline and at the 12-month visit.
|
Patients will undergo atropine testing consisting of an intravenous bolus of atropine sulfate. ECG will be recorded immediately before and 5 minutes after the injection. |
Baseline and at the 12-month visit.
|
|
Vagal atrial induction test (VAFIT)
Zeitfenster: Periprocedural
|
This test will be performed to assess the inducibility of AF/AF at baseline and at the end of the procedure. The induction protocol will use programmed atrial stimulation (a short train of 4 cycles at 120 bpm followed by one extrastimulus) from the low lateral right atrium, synchronised with the ECVS. |
Periprocedural
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IClinicalEM
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .